| 1 | home about us overview | | | | | | | 1 | 0.49% |
| 2 | results the company is | | | | | | | 1 | 0.49% |
| 3 | extensive preclinical animal studies | | | | | | | 1 | 0.49% |
| 4 | preclinical animal studies recent | | | | | | | 1 | 0.49% |
| 5 | elucidation of molecular mechanisms | | | | | | | 1 | 0.49% |
| 6 | of molecular mechanisms and | | | | | | | 1 | 0.49% |
| 7 | molecular mechanisms and published | | | | | | | 1 | 0.49% |
| 8 | mechanisms and published human | | | | | | | 1 | 0.49% |
| 9 | and published human clinical | | | | | | | 1 | 0.49% |
| 10 | the company is advancing | | | | | | | 1 | 0.49% |
| 11 | based on extensive preclinical | | | | | | | 1 | 0.49% |
| 12 | company is advancing an | | | | | | | 1 | 0.49% |
| 13 | is advancing an entirely | | | | | | | 1 | 0.49% |
| 14 | advancing an entirely novel | | | | | | | 1 | 0.49% |
| 15 | an entirely novel treatment | | | | | | | 1 | 0.49% |
| 16 | entirely novel treatment paradigm | | | | | | | 1 | 0.49% |
| 17 | based on multisite direct | | | | | | | 1 | 0.49% |
| 18 | on multisite direct current | | | | | | | 1 | 0.49% |
| 19 | on extensive preclinical animal | | | | | | | 1 | 0.49% |
| 20 | sclerosis based on extensive | | | | | | | 1 | 0.49% |
| 21 | direct current stimulation multisite | | | | | | | 1 | 0.49% |
| 22 | are focused on rapidly | | | | | | | 1 | 0.49% |
| 23 | enable the treatment of | | | | | | | 1 | 0.49% |
| 24 | the treatment of patients | | | | | | | 1 | 0.49% |
| 25 | treatment of patients with | | | | | | | 1 | 0.49% |
| 26 | of patients with serious | | | | | | | 1 | 0.49% |
| 27 | patients with serious neurological | | | | | | | 1 | 0.49% |
| 28 | with serious neurological disorders | | | | | | | 1 | 0.49% |
| 29 | we are focused on | | | | | | | 1 | 0.49% |
| 30 | focused on rapidly bringing | | | | | | | 1 | 0.49% |
| 31 | and als amyotrophic lateral | | | | | | | 1 | 0.49% |
| 32 | on rapidly bringing to | | | | | | | 1 | 0.49% |
| 33 | rapidly bringing to market | | | | | | | 1 | 0.49% |
| 34 | about us overview management | | | | | | | 1 | 0.49% |
| 35 | to market revolutionary products | | | | | | | 1 | 0.49% |
| 36 | for noninvasively treating spasticity | | | | | | | 1 | 0.49% |
| 37 | noninvasively treating spasticity and | | | | | | | 1 | 0.49% |
| 38 | treating spasticity and als | | | | | | | 1 | 0.49% |
| 39 | spasticity and als amyotrophic | | | | | | | 1 | 0.49% |
| 40 | multisite direct current stimulation | | | | | | | 1 | 0.49% |